Kinoxis Therapeutics

Executive Summary

Kinoxis Therapeutics is an Australian clinical-stage biotech developing first-in-class small-molecule therapies for CNS disorders with high unmet need. Its lead candidate, KNX100, is a novel ALOX15 inhibitor targeting agitation and aggression in dementia—a symptom cluster lacking approved treatments. The company’s second program, KNX101, is an oxytocin-receptor partial agonist designed for acute and chronic pain, offering a non-opioid alternative. Both assets are built on proprietary platforms with potential in other neuropsychiatric indications. Founded in 2020 and headquartered in Melbourne, Kinoxis has raised $21M and is currently advancing KNX100 through Phase 2 trials. The company’s differentiated mechanistic approach and focus on underserved CNS conditions position it as an attractive player in the neuropsychiatric space. With Phase 2 data for KNX100 and early-stage progress for KNX101, Kinoxis represents a high-risk, high-reward opportunity for investors seeking exposure to innovative CNS therapies.

Upcoming Catalysts (preview)

• Q2 2026Phase 2 top-line data for KNX100 in dementia-related agitation45% success
• Q4 2026Initiation of Phase 1/2 trial for KNX101 in chronic pain70% success
• TBDPotential partnership for Asian rights or co-development30% success